Novel use of combination of sacubitril and valsartan
The use of sacubitril and valsartan in a 1:1 molar ratio addresses the lack of effective treatments for pediatric heart failure by enhancing natriuretic peptide activity and reducing sympathetic tone, achieving improved clinical outcomes in pediatric patients.
Patent Information
- Application Number
- JP2024141820
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2016-09-12
- Filing Date
- 2024-08-23
- Publication Date
- 2024-11-13
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Current treatments for pediatric heart failure in children lack prognostic benefit, as evidenced by clinical trials showing no significant improvement in heart failure symptoms or outcomes, and existing drugs are based on adult trial results without consideration for the unique pathophysiology of pediatric heart failure.
Administer a combination of sacubitril and valsartan in a 1:1 molar ratio to pediatric patients, utilizing the drug LCZ696, which inhibits neprilysin and angiotensin receptors to enhance natriuretic peptide activity, reducing sympathetic tone and renin-angiotensin system activation, thereby addressing the underlying pathophysiology of pediatric heart failure.
The combination of sacubitril and valsartan in a 1:1 molar ratio demonstrates significant mortality and morbidity benefits in pediatric patients with heart failure, comparable to adult heart failure treatments, by reducing left ventricular ejection fraction and improving clinical outcomes.
Smart Images

Figure 2024160386000001 
Figure 2024160386000002 
Figure 2024160386000003
Abstract
Description
[Technical field]
[0001] The present invention relates to methods and pharmaceutical compositions for treating heart failure in pediatric human patients. In addition, a combination of a therapeutic agent that blocks angiotensin receptors and a therapeutic agent that inhibits the NEP enzyme is In particular, a therapeutically or prophylactically effective amount of the combination of Sacubitril and Valsartan is administered to a pharmaceutical and administering to said patient in a commercially acceptable form and in a 1:1 molar ratio. and pharmaceutical compositions.
[0002] 2. Background of the Invention Heart Failure in Pediatric Patients Pediatric heart failure (HF) is associated with significant morbidity and mortality, frequent hospitalizations and medical care, It is characterized by a decline in quality of life and a decline in the quality of life. It is estimated that 10,000 children aged 19 years or younger will be diagnosed with HF. HF is a common condition in childhood, adolescence, and During childhood and even into adulthood, as evidenced by the increasing number of adults with congenital heart disease Congenital heart disease and cardiomyopathies are the most common causes of pediatric HF. There are two main reasons for this.
[0003] The greatest burden of HF comes from children born with congenital malformations. Congenital heart disease occurs in approximately 8 out of every 1,000 live births, of which 1,000 One to two people per 100 will develop HF. Ventricular or atrial septal defects, patent ductus arteriosus, persistent aortopulmonary bypass Arterial connection, hypoplastic left heart, aortic or pulmonary vein stenosis, anomalous origin of left coronary artery, and aortic stenosis A variety of congenital anomalies may be present, including glaucoma. Most of these children are diagnosed before the age of one year. Many undergo early surgical intervention, usually before the age of two.
[0004] The other major cause of pediatric HF is cardiomyopathy, with the majority of cases occurring in the US, Australia, the UK and Ireland. Dilated cardiomyopathy has an estimated annual incidence of 1 per 10,000 children in the UK. (usually diagnosed as idiopathic, familial, or myocarditis) are the most common types. Hypertrophic cardiomyopathy due to isolated familial cardiomyopathy, inborn errors of metabolism or malformation syndromes are the next most common. Cardiomyopathy is the most common type of cardiomyopathy in Duchenne muscular dystrophy and myotonic dystrophy. In developing countries, it is associated with rheumatic heart disease, malnutrition and Other tropical diseases, such as Gervais disease, may also be substantial causes of pediatric HF.
[0005] The clinical course and outcome of pediatric HF depends on the etiology. After congenital heart surgery, HF is characterized by myocardial infarction. It may still develop for a number of reasons, including systolic dysfunction.
[0006] Many pediatric patients with severe HF are usually referred for heart transplantation, when available. However, heart transplantation is usually hampered by limited availability of donor organs, a complex clinical course, and In the United States, One in four infants listed for heart transplants will die before a donor heart becomes available. Furthermore, nearly 40% of children with symptomatic cardiomyopathy in the United States undergo heart transplantation or die within 2 years. Either that or they will die within a year.
[0007] In contrast to HF in adults, research on pediatric HF is very limited. Treatment of HF in children is based on information and results from adult studies For information on pediatric HF management, see the International Society of Hematology. Published by the Institute of Transplantation of Stomach and Lungs (ISHLT) This is outlined in recent published guidelines (Kirk R, Dipchand AI, Rosenthal DN, et al. t al. (2014) The international society for heart and lung transplantation guidel ines for the management of pediatric heart failure: Executive summary. J Heart L ung Transplant; 33:888-909). Diovan Pediatric Heart Fa Respondents to the ilure Survey were asked about the efficacy shown in adult HF clinical trials and and Consensus Statements and Guidelines to inform treatment decisions for pediatric patients with HF. We confirmed that these are the two most important factors to consider when selecting a , 2011). According to this survey of pediatric cardiologists, the current clinical management of pediatric HF includes Otensin-converting enzyme inhibitors (ACEIs), angiotensin receptor blockers (ARBs), beta -blockers, diuretics, aldosterone-blocking drugs, digoxin and anticoagulants.
[0008] In this regard, clinical trials have not demonstrated the prognostic benefit of any drug therapy in children with HF. The largest pediatric HF trial conducted to date has not shown whether patients with congenital or ventricular disease have A randomized, double-blind study of carvedilol in patients aged 8 months to 14 years with myopathic HF. This is a placebo-controlled, parallel-group clinical trial (Shaddy RE, Boucek MM, Hsu DT, et al. (2007 ) Carvedilol for children and adolescents with heart failure: A randomized contr olled trial. JAMA; 298:1171-1179. The primary endpoint of the pediatric carvedilol study was , a composite index of HF prognosis, and response to treatment was assessed as worsening, improved, or unchanged. The adult HF population showed benefit from β-blockade, but this study did not demonstrate a significant benefit for its primary composite endpoint. This is due to the various causes of HF, the uncertain natural history of HF in children, and Issues commonly associated with pediatric HF clinical trials include medical history and clinical trial design challenges specific to the pediatric population. This may have been due to a known issue with
[0009] Sacubitril and Valsartan (LCZ696) LCZ696 is being developed for the treatment of cardiovascular diseases such as hypertension and / or heart failure. A first-in-class angiotensin receptor neprilysin inhibitor LCZ696 is an anionic form of sacubitril and valsartan. The solid phase contains sodium cations and water molecules in a molar ratio of 1:1:3:2.5. The asymmetric unit cell of the crystal has a ratio of 6:6:18:15, which is shown in the following formula: Therefore we present:
[0010] [ka]
[0011] The molecule on the left is the NEP inhibitor prodrug sacubitril (AHU377, (2R,4S) -5-Biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl N-pentanoic acid ethyl ester, also known as N-(3-carboxyl-1-oxopropyl) -(4S)-(p-phenylphenylmethyl)-4-amino-(2R)-methylbutanoic acid Ethyl ester; IUPAC name 4-{[(1S,3R)-1-([1,1'-biphenyl ]-4-ylmethyl)-4-ethoxy-3-methyl-4-oxobutyl]amino}-4- oxobutanoic acid), while the molecule on the right is a known angiotensin receptor blocker (A The figure illustrates valsartan, which is an anti-inflammatory drug.
[0012] Ingestion of LCZ696 induces the formation of the active form of LBQ657 (2R,4S)-5-biphenyl-4-isopropyl 4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid Sacubitril, which inhibits angiotensin II type 1 (AT1) receptors, and Valproate, which inhibits angiotensin II type 1 (AT1) receptors. Systemic exposure to the sartan is achieved at a 1:1 molar ratio.
[0013] Sacubitril and Valsartan Combination, Particularly LCZ696 and Its Formulations To date, the company has published International Publication No. 2003 / 059345 and International Publication No. 2007 / 056546 and WO 2009 / 061713 , which are incorporated herein by reference.
[0014] Mechanism of action: Neprilysin inhibition inhibits physiologically active atrial natriuretic peptide (ANP) and It enhances the levels of the potent natriuretic peptides (NPs). NPR-A and its second messenger, cyclic GMP (cGMP), They mediate their cardiovascular effects through activation of vasodilator, sodium Increased urinary excretion, diuresis, and renin angiotensin II by reducing renin and aldosterone release Inhibition of the aldosterone-associated vasopressin system (RAAS), reducing sympathetic drive, and Has antiproliferative and antihypertrophic effects on vascular endothelial and smooth muscle cells. The angiotensin receptor blocker (ARB) component provides AT1 receptor antagonism and inhibits angiotensin Prevents the deleterious effects of II, thereby lowering peripheral vascular resistance. Dual, potentially complementary By delivering multiple beneficial effects, LCZ696 may help patients with cardiovascular and renal disease This can provide clinical benefit to patients.
[0015] Sacubitril and Valsartan for the Treatment of Patients with Cardiovascular and / or Renal Disease Various uses of the combination, in particular of LCZ696, are described, for example, in WO 2003 / 05 Pamphlet No. 9345, International Publication No. 2007 / 056546, International Publication Brochure No. 2012 / 027237, Brochure No. WO 2014 / 029848 Lett., WO 2015 / 030711 and WO 2015 / Described in pamphlet No. 028941.
[0016] In particular, chronic oral administration of LCZ696 inhibited neprilysin (NEP) and reduced cardiac Natriuretic peptide secreted by the heart in response to stress and increased intravascular volume. Stimulates the body's intrinsic ability to compensate for heart failure (HF) exacerbations by increasing peptide activity. Unlike any other treatment for HF, LCZ696 can improve NE Provides simultaneous inhibition of P and angiotensin type 1 (AT1) receptors. Blockade of the AT1 receptor by inhibition of the renin-angiotensin-aldosterone system (RAAS) The increased natriuretic peptide (NP) activity obtained from These drugs have complementary beneficial effects in patients with HF.
[0017] PARADIGM-HF (CLCZ696B2314; N=8442), reduced ejection fraction In a pivotal Phase 3 study in adult patients with HFrEF, LCZ696 , in delaying the time to the first occurrence of the composite endpoint of CV death or HF hospitalization. 20% relative risk reduction (RRR) (p=0.0000002) compared with enalapril (standard In addition, LCZ696 was superior to placebo in delaying time to CV death by 20 %RRR (p=0.00004), 21%RR in delay to first HF hospitalization PARADIGM-HF was superior to enalapril in terms of R (p=0.00004). LCZ696 has also been shown to be generally safe and well tolerated in adult patients with HF. showed (McMurray et al., 2014).
[0018] Need: As mentioned above, in this regard, clinical trials are currently underway to evaluate the efficacy and safety of any drug in children with HF. Therefore, the authors did not demonstrate any prognostic benefit of chemotherapy for cardiovascular disease such as heart failure (HF). The need for novel agents for use in children as alternatives to currently available treatments for is strong.
[0019] Summary of the Invention The present invention relates to methods and pharmaceutical compositions for treating heart failure (HF) in pediatric human patients. A therapeutic agent that blocks angiotensin receptors and a therapeutic agent that inhibits the NEP enzyme. A therapeutically effective or prophylactically effective amount of a combination of drugs, particularly a combination of Sacubitril and Valsartan administering to said patient an amount of 1:1 in a pharma- ceutically acceptable form and in a molar ratio of 1:1; Methods and pharmaceutical compositions.
[0020] Rationale: In both pediatric and adult HF due to systolic dysfunction, there is a reduction in systemic ventricular output. The pathophysiological adaptation to reduced cardiac output for both adult and pediatric HF is increased sympathetic tone. and activation of the renin-angiotensin system (RAS). Similarly, pediatric HF results in increased activation of the natriuretic peptide system. Pathophysiological neurohumoral activation contributes to the progression of HF due to systolic dysfunction in adults and children Therefore, this subgroup of pediatric HF patients with systemic left ventricular systolic dysfunction plays an important role. Management of heart failure in HFrEF is similar to that in adults with HFrEF.
[0021] In one embodiment, the present invention provides a subset of pediatric HF patients with systemic left ventricular systolic dysfunction. The subset focused on the efficacy and safety of LCZ696 compared to the current standard of care (ACEI). demonstrated significant mortality and morbidity benefits compared with adult HFrEF (McMurray 2014) It is a more homogenous pediatric HF population that also has similar pathophysiology.
[0022] It is the standard of care to reduce mortality and morbidity in adult patients with HFrEF. The efficacy of LCZ696 over enalapril was demonstrated by the fact that LCZ696 reduced left ventricular ejection fraction (LVEF There is a strong theoretical justification for the study to have clinically meaningful benefit in pediatric HF patients with reduced Provide evidence: Causes of pediatric and adult HF with systolic dysfunction (or reduced LVEF) Despite differences in theories, there is evidence of symptomatic systemic left ventricular systolic dysfunction between both populations. In pediatric patients, there are similarities in pathophysiology and clinical management.
[0023] Thus, the present disclosure provides a method for preventing or treating heart failure in human pediatric patients in need of such treatment. In a first embodiment, a method for preventing or treating malformation is provided, comprising administering to the subject a 1:1 molar ratio of succinylcholine chloride. A therapeutically or prophylactically effective amount of a combination of tolyl and valsartan is administered to said patient. The present invention is directed to a method including the steps of:
[0024] Such a combination of Sacubitril and Valsartan may be, for example, in a molar ratio of 1:1. (i) valsartan or a pharma- ceutically acceptable salt thereof; and (ii) Sacubitril or a pharma- ceutically acceptable salt thereof The present invention relates to a pharmaceutical composition comprising a therapeutically or prophylactically effective amount of the combination.
[0025] In one embodiment thereof, the combination has formula (I): [(A1)(A2)](Na + ) y ×H2O(I) (In the formula, A1 is the anionic form of valsartan; A2 is the anionic form of Sacubitril; Na + is the sodium ion; y is 1 to 3; (x is 0 to 3) The compound is provided in the form of:
[0026] In one embodiment thereof, the compound of formula (I) is [3-((1S,3R)-1-biphenyl] (4-ylmethyl-3-ethoxycarbonyl-1-butylcarbamoyl)propion Acid -(S)-3'-methyl-2'-(pentanoyl{2''-(tetrazol-5-yl) Trisodium ethyl (4'-ethyl)biphenyl-4'-ylmethyl (amino)butyrate hemipentahydrate (LCZ696).
[0027] In one embodiment, the pharmaceutical composition further comprises one or more pharma- ceutically acceptable carriers. Included.
[0028] In a second aspect, the present invention provides a method for preventing or treating heart failure in a human pediatric patient. The present invention is directed to the use of a pharmaceutical composition as defined above for the manufacture of a medicament for treating
[0029] In a third aspect, the present invention provides a method for preventing or treating heart failure in a human pediatric patient. The present invention is directed to a pharmaceutical composition as defined above.
[0030] In a fourth aspect, the present invention provides a method for preventing or treating heart failure in a human pediatric patient. The present invention relates to the use of a pharmaceutical composition as defined above.
[0031] Further features and advantages of the disclosure will become apparent from the following detailed description of the invention. It is thought.
[0032] definition Throughout the specification and claims that follow, unless expressly stated otherwise, the following terms are defined as follows. Each of the following definitions may be used independently, above or below: Any more specific interpretation of any or all of the general terms used herein (to the extent that they exist) Thus, more specific embodiments of the invention can be defined:
[0033] The term "prevention" refers to prophylactic administration to a healthy subject to prevent the onset of the conditions described herein. In addition, the term "prevention" refers to the prevention of a condition in a patient who is in a pre-stage of the condition to be treated. This means prophylactic administration of
[0034] The term "treatment" is understood to mean the management and care of a patient for the purpose of combating a disease, condition or disorder. will be done.
[0035] The term "effective amount" or "therapeutically effective amount" refers to the amount sought by a researcher or clinician. to induce a desired biological and / or medical response in a tissue, system or animal (including a human). In particular, the term "effective amount" or A "therapeutically effective amount" refers to an amount that is sufficient to halt or reduce the progression of the condition being treated, e.g., chronic heart failure. or else have an active ingredient that completely or partially cures or palliates the condition. Or it refers to the amount of drug.
[0036] The term "patient" includes humans, dogs, cats, horses, pigs, cows, monkeys, rabbits, and mice. The preferred patient is a human.
[0037] The terms "administration of" or "administering" a compound refer to administering a compound of the invention to a subject in need of treatment. or a pharma- ceutically acceptable salt or ester thereof, or a prodrug thereof. It should be understood that the present invention relates to a composition for carrying out the treatment of the present method. is administered to a subject in need of such treatment or prevention in a therapeutically effective amount of the compound in the composition. The need for prophylactic administration according to the methods of the present invention is based on well-known The effective amount of each compound will be determined by the attending physician in each case. The exact disease to be treated, the disease the patient is suffering from and other factors will be determined in the final analysis. the severity of the disease or condition, the chosen route of administration, and any other medications the patient may require concomitantly. It depends on factors such as the drug and treatment, as well as other factors at the physician's discretion.
[0038] As used herein, the term "prophylactically effective amount" refers to the amount sought by a researcher, veterinarian, physician, or other clinician. Inducing a biological or medical response in a tissue, system, subject or human subject to induce atrial enlargement. and / or of diseases characterized by and / or manifested by remodeling. It refers to the amount of active compound in the composition that prevents the onset of disease.
[0039] As used herein, the term "about" refers to a value of + / - 20%, + / - 10%, or + / - 5%. This refers to:
[0040] As used herein, the term "pharmaceutical acceptable" means that which is reasonably within the scope of sound medical judgment. The potential for excessive toxicity, irritation, allergic responses, and other problems is comparable to the expected benefit / risk ratio. Compounds, materials and compositions suitable for contact with mammalian, particularly human, tissue without significant complications This refers to the product and / or dosage form.
[0041] Within the scope of this application, the term "mini-tablet" refers to tablets in uncoated form. about 2 to 30 mg, for example about 4 to 9 mg, for example about 7 mg, and In a dosed form, about 2.2 to 32 mg, for example about 4.1 to 10 mg, for example A mini tablet is defined herein as a small tablet having a total weight of about 7.1 to 7.5 mg. They are specific forms of multi-particles that are defined as particles, granules or beads. They can be prepared as described herein, including from smaller multiparticulates. Mini-tablets can be of any shape known to those skilled in the art for tablets, e.g., circular, e.g., about 1. 25 to 3 mm or as defined elsewhere herein; e.g., a convex upper surface and and a cylindrical shape having a convex lower surface, the diameter and height of the cylindrical shape being independently variable, e.g. , 1 to 3 mm or as defined elsewhere herein; or, for example, height and Approximately equal in diameter, 1.25 to 3 mm, or as defined elsewhere herein The tablet may be a biconvex mini-tablet.
[0042] The New York Heart Association (NYHA) classification has four categories: The NYHA classification grades the severity of heart failure symptoms as one of the functional classes. Standard descriptions of severity that can be used to assess response to therapy and guide management It is widely used in clinical practice and research because it provides insight into the severity and condition of symptoms. New York Heart Association Functional Classification based on physical activity: Class I: No limitation of physical activity. Ordinary physical activity is not accompanied by excessive shortness of breath, fatigue or Does not cause palpitations. Class II: Mild restriction of physical activity. Stable at rest but not normal. Activity causes excessive shortness of breath, fatigue, or palpitations. Class III: Physical activity is severely restricted. Stable at rest, but less than normal. Unnecessary physical activity results in excessive shortness of breath, fatigue, or palpitations. Class IV: Any physical activity cannot be continued without pain. Symptoms at rest may be present. Any physical activity increases the pain.
[0043] Choice of endpoint: Both cardiovascular death and hospitalization for heart failure are associated with progression of the heart failure syndrome. Associated with deterioration and reflects disease-specific endpoints experienced by patients with systolic heart failure These endpoints can be modified by treatments that improve the condition. The condition can be treated with drugs such as ACEIs, aldosterone antagonists and β-blockers, as well as cardiac It has generally proven to be the case for the use of devices for cardiac resynchronization therapy.
[0044] As used herein, the term "sacubitril and valsartan in a molar ratio of 1:1" refers to a 1:1 molar ratio of sacubitril and valsartan. :1 (i) valsartan or a pharma- ceutically acceptable salt thereof; and (ii) Sacubitril or a pharma- ceutically acceptable salt thereof The term "combination therapy" refers to a combination comprising a therapeutically effective amount of
[0045] Sacubitril is N-(3-carboxy-1-oxopropyl)-(4S)-(p-phenylalanine). (phenylphenylmethyl)-4-amino-2R-methylbutanoic acid ethyl ester INN This is (2R,4S)-5-biphenyl-4-yl-4-(3-carboxy- Sacubitril is a prodrug of (propionylamino)-2-methyl-pentanoic acid. No. 5,217,996, which is incorporated herein by reference. The compound can be prepared by known methods such as those described above.
[0046] Valsartan is a serotype of SN-valeryl-N-{[2'-(1H-tetrazol-5-yl )-biphenyl-4-yl]-methyl}-valine. Valsartan or (S)- N-valeryl-N-{[2'-(1H-tetrazol-5-yl)-biphenyl-4-yl
[0111] 1-methyl-valine) or a pharma- ceutically acceptable salt thereof was purchased from a commercial source. or as described in U.S. Pat. No. 5,399,578 and European Patent No. 044 The preparation can be carried out according to known methods, such as those described in the specification of US Pat. No. 3,983. The teachings of which are incorporated herein by reference. Valsartan is a compound which is useful in certain embodiments of the present invention. In the present invention, the compound may be used in the free acid form or in any suitable salt form. , esters or other derivatives of the carboxylic acid group can be used, as well as tetrazoles. Salts and derivatives of the groups can be used.
[0047] In one embodiment thereof, the combination is in a molar ratio of 1:1 (i) valsartan; and (ii) Sacubitril or its pharma- ceutically acceptable salts, such as sodium or calcium salts. Including salts of.
[0048] In another embodiment thereof, the combination comprises a compound of formula (I) [(A1)(A2)](Na + ) y ×H2O(I) (In the formula, A1 is the anionic form of valsartan; A2 is the anionic form of Sacubitril; Na + is the sodium ion; y is 1 to 3, preferably 1, 2 or 3; x is 0 to 3, preferably 0, 0.5, 1, 1.5, 2, 2.5 or 3. The compound is provided in the form of:
[0049] In one embodiment, y is 3 and x is 2.5.
[0050] In particular, the compound is [3-((1S,3R)-1-biphenyl-4-ylmethyl-3-phenylene] (S)-3'-methyl-2-methoxycarbonyl-1-butylcarbamoylpropionate '-(Pentanoyl{2''-(tetrazol-5-yl)ate)biphenyl-4'-yl (methyl)amino)butyric acid trisodium hemipentahydrate (LCZ696).
[0051] In a preferred embodiment, the compound [3-((1S,3R)-1-biphenyl-4-yl] (S)-(3-ethoxycarbonyl-1-butylcarbamoyl)propionic acid 3'-Methyl-2'-(pentanoyl{2''-(tetrazol-5-yl) ester) Trisodium (phenyl-4'-ylmethyl)aminobutyrate hemipentahydrate is in the crystalline form It exists in.
[0052] The corresponding active ingredient or a pharma- ceutically acceptable salt thereof may also be used in the form of a hydrate. , or other solvents used in crystallization.
[0053] Preferably, the compounds Sacubitril or a salt thereof, Valsartan or a salt thereof, The LCZ696 is substantially pure or in substantially pure form. By "substantially high purity" is meant at least about 90% pure, more preferably at least about 9 5%, and most preferably at least about 98% purity.
[0054] It is also preferred that these compounds are solids or in a solid form or state. A solid, solid form or solid state may be crystalline, partially crystalline, amorphous or polyamorphous, preferably Preferably it is in crystalline form.
[0055] The term "sacubitril and valsartan in a molar ratio of 1:1" refers to valsartan and sacubitril. cubitril, optionally linked to a non-covalent or covalent bond via a linker Thus, it can also refer to alternative complexes or compounds that link them together.
[0056] Detailed Description of the Invention As mentioned above, in this regard, clinical trials are currently underway to evaluate the efficacy and safety of any drug in children with HF. Therefore, the authors did not demonstrate any prognostic benefit of chemotherapy for cardiovascular disease such as heart failure (HF). The need for novel agents for use in children as alternatives to currently available treatments for is strong.
[0057] The present invention relates to the drug LCZ696 (i.e., Sacubitril and Valsalta in a molar ratio of 1:1). The study found that pediatric patients with bronchitis may benefit from the use of bronchodilators, which may be particularly beneficial in improving or reducing heart failure. These findings differentiate LCZ696 from currently available cardiovascular drugs for children. Disclose.
[0058] In particular, it is an object of the present invention to provide a treatment for pediatric heart failure patients, 96 used global rank endpoints in pediatric HF patients. It is superior to enalapril for the treatment of heart failure as assessed using
[0059] It is also an object of the present invention to provide a treatment for pediatric heart failure patients, 96 is the first occurrence or progression of a composite of category 1 and 2 events (e.g., death and worsening HF). It is superior to enalapril in reducing the time spent in the
[0060] In another embodiment, it is an object of the present invention to provide treatment for pediatric heart failure patients. and LCZ696 was more effective than enalapril in improving NYHA / Ross functional class. Better.
[0061] Thus, the present invention relates to:
[0062] Treatment Method Thus, the present invention relates to a method for preventing or treating heart failure in a human pediatric patient in need of such treatment. A method for preventing or treating psoriasis comprising administering to said patient a 1:1 molar ratio of sacubitril and balsamin. administering to said patient a therapeutically or prophylactically effective amount of a combination of It encompasses the law.
[0063] In a preferred embodiment, the human pediatric patient is between 1 month and less than 18 years of age.
[0064] In one embodiment, the patient suffers from chronic heart failure caused by left ventricular systolic dysfunction. do.
[0065] In one embodiment, the patient is 6 to under 18 years of age and is in NYHA class II, II Patients had stage I or IV heart failure or were under 6 years of age and had a Ross HF rating of 1. Patients with class II to IV heart failure.
[0066] In another embodiment, the patient has a systemic ventricular ejection fraction of ≦40%, preferably ≦35. (LVEF), or have a shortening fraction of ≤20%.
[0067] In one embodiment, the patient is a patient with a congenital heart defect with systemic ventricular systolic dysfunction; an idiopathic heart defect; Myopathy; familial / hereditary and / or genetic cardiomyopathy; history of myocarditis; neuromuscular disorders; congenital metabolic disorders; mitochondrial disorders; acquired (chemotherapy, iatrogenic, infectious, rheumatic, nutritional Heart failure selected from the following: nutritional; ischemic (e.g., Kawasaki disease, postoperative); and left ventricular noncompaction Has etiology.
[0068] In one embodiment thereof, the patient is in NYHA class II or higher due to left ventricular systolic dysfunction. The patient suffers from chronic heart failure classified as III or IV, and the patient has a heart rate of ≦40%, preferably Have a reduced left ventricular ejection fraction (LVEF) of ≦35%.
[0069] In another embodiment thereof, administration reduces cardiovascular death and cardiovascular mortality due to heart failure in said patient. Reduce the risk of hospitalization.
[0070] In one embodiment thereof, a combination of Sacubitril and Valsartan in a molar ratio of 1:1. A therapeutically or prophylactically effective amount is from about 10 mg to about 500 mg of succinylcholine in a 1:1 molar ratio. Includes the total daily dose of the combination of tolyl and valsartan.
[0071] In another embodiment thereof, a combination of Sacubitril and Valsartan in a molar ratio of 1:1. A therapeutically or prophylactically effective amount of Preferably, the amount of sacubitril and valsartan is approximately 6 mg / kg body weight in a 1:1 molar ratio. In one embodiment, the total daily dose of the combination is 1:1 molar ratio of Sacubitril and The therapeutically or prophylactically effective amounts of the combination of valsartan and valsartan are 1.0, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2.0, 2.1, 2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8, 2.9, 3.0, 3.1, 3.2, 3.3, 3.4, 3.5, 3.6, 3.7, 3.8, 3.9, 4.0, 4.1, 4.2, 4.3, 4.4, 4.5, 4.6, 4.7, 4.8, 4.9, 5.0, 5.1, 5.2, 5.3, 5.4, 5.5, 5.6, 5.7, 5.8, 5.9, 6.0, 6.1, 6.2, 6.3, 6.4, 6.5, 6.6, 6.7, 6.8, 6.9, 7.0, 7.1, 7.2, 7.3, 7.4, 7.5, 7.6, 7.7, 7.8, 7.9 and 8.0 mg / kg patients Sacubitril in a molar ratio of 1:1, particularly 6.2 mg / kg body weight, and Includes the total daily dose of the valsartan combination.
[0072] In one embodiment thereof, the combination of Sacubitril and Valsartan in a molar ratio of 1:1 is The drug is administered to the patient once or twice a day, preferably twice a day.
[0073] In another embodiment thereof, a combination of Sacubitril and Valsartan in a molar ratio of 1:1. A therapeutically or prophylactically effective amount of 5-HT is approximately 2 mg / kg of patient body weight per dose administered twice daily. about 4 mg / kg body weight, preferably about 3 mg / kg body weight, in a molar ratio of 1:1. In one embodiment, the combination of sucrose and valsartan is The therapeutically or prophylactically effective amount of the combination of Vitril and Valsartan is 20 mg once daily. Single dose 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9 , 1.0, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9 , 2.0, 2.1, 2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8, 2.9 , 3.0, 3.1, 3.2, 3.3, 3.4, 3.5, 3.6, 3.7, 3.8, 3.9 , 4.0, 4.1, 4.2, 4.3, 4.4, 4.5, 4.6, 4.7, 4.8, 4.9 and 5.0 mg / kg patient body weight, in particular 3.1 mg / kg body weight. Contains a 1:1 combination of sacubitril and valsartan.
[0074] In another embodiment thereof, a combination of Sacubitril and Valsartan in a molar ratio of 1:1. Each tablet contains 3.125 mg of active ingredient (sacubitril and valsal in a 1:1 molar ratio). In the form of mini-tablets each containing 50 mg, 100 mg or or 200 mg of each ingredient (sacubitril and valsartan in a 1:1 molar ratio). The drug is administered to the patient in the form of a tablet having the formula:
[0075] In another embodiment, a 1:1 molar ratio of Sacubitril and Valsartan is [3-((1S,3R)-1-biphenyl-4-ylmethyl-3-ethoxycarbonyl- (S)-3'-methyl-2'-(pentanoyl)propionate (1-butylcarbamoyl) {2''-(tetrazol-5-yl)biphenyl-4'-ylmethyl}amino) butyrate] trisodium hemipentahydrate (LCZ696).
[0076] In one embodiment of the invention, which applies to all of the above treatment options, a pharmaceutical composition is administered and about 10 mg to about 500 mg, particularly about 400 mg, of sacubitril in a molar ratio of 1:1. and valsartan to deliver the full daily dose of the combination.
[0077] In particular, the pharmaceutical composition is administered to provide a combination of sacubitril and valsartan in a molar ratio of 1:1. It is delivered in doses of 50 mg, 100 mg or 200 mg once or twice daily. For example, a 1:1 molar combination of sacubitril and valsartan would be , 100 mg or 200 mg is administered to patients once or twice daily.
[0078] In one embodiment thereof, a) A 50 mg dose of sacubitril and valsartan in a 1:1 molar ratio is sacubitril Corresponding to 24mg and valsartan 26mg, b) A 100 mg dose of Sacubitril and Valsartan in a 1:1 molar ratio is 49 mg of valsartan and 51 mg of valsartan. c) Sacubitril and valsartan in a 1:1 molar ratio at a dose of 200 mg is corresponding to 97 mg of valsartan and 103 mg of valsartan.
[0079] In another embodiment, a 1:1 molar ratio of Sacubitril and Valsartan is Each tablet contains 3.125 mg of active ingredients (sacubitril and valsartan in a 1:1 molar ratio). The exact dosage given to each patient is: Determined based on body weight as described above, i.e. to achieve a molar ratio of 1:1 saccharin The combined dose of Vitril and Valsartan administered twice daily is approximately 2 mg / kg patient. from about 4 mg / kg body weight, preferably about 3 mg / kg body weight, in particular 3.1 mg / kg kg body weight. For example, for a 20 kg child, a single dose of 3 mg / kg is administered twice daily. Corresponding to a 60 mg dose of the combination of active ingredients to be administered. Single dose of 3.1 mg / kg corresponds to a 62 mg dose of the combination of active ingredients administered twice daily.
[0080] The 60 mg dose consists of approximately 19 mini-tablets, each containing 3.125 mg of active ingredient, is equivalent to one 50 mg regular tablet and three mini tablets.
[0081] The 62 mg dose consists of approximately 20 mini-tablets each containing 3.125 mg of active ingredient, is equivalent to one 50 mg regular tablet and four mini tablets.
[0082] In one embodiment of the invention, the mini-tablets are administered via a capsule, e.g. A capsule can contain a defined number of mini-tablets. The number can be 1, 2, 3, 4 , 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 and 20; preferably the container, preferably the capsule, is selected from 4 or containing 10 mini tablets.
[0083] In certain embodiments of the pharmaceutical composition, Sacubitril and Valsalta in a molar ratio of 1:1. The combination of phenylene is the compound [3-((1S,3R)-1-biphenyl-4-ylmethyl-3- Ethoxycarbonyl-1-butylcarbamoyl)propionic acid-(S)-3'-methyl- 2'-(pentanoyl{2''-(tetrazol-5-yl)ate)biphenyl-4'- Delivered in the form of trisodium (methyl)amino)butyrate hemipentahydrate (LCZ696) Achieved, a) Sacubitril and valsartan 50 mg in a 1:1 molar ratio are approximately Corresponding to 56.6mg, b) Sacubitril and valsartan 100 mg in a 1:1 molar ratio were That corresponds to 113.1 mg. c) Sacubitril and valsartan 200 mg in a 1:1 molar ratio were That corresponds to 226.2 mg. d) Sacubitril and valsartan 3.125 mg in a 1:1 molar ratio is LCZ696 This corresponds to approximately 3.534 mg.
[0084] In one embodiment of the above, the combination of Sacubitril and Valsartan is It may be delivered in the form of a pharmaceutical composition further comprising one or more pharma- ceutically acceptable carriers.
[0085] In another embodiment, the patient is treated with a medicament for preventing or treating the risk of experiencing a recurrent cardiovascular event. Patients are concurrently receiving standard medical treatment to reduce or eliminate the risk of developing glaucoma.
[0086] In further embodiments, the standard of care treatment includes beta blockers, aldosterone antagonists, Treatment with stable doses of antidiabetics and / or diuretics is included.
[0087] In an alternative embodiment, the standard of care treatment comprises a beta-blocker and optionally an agonist. Treatment with a stable dose of a ludostatin antagonist is included.
[0088] All of the above-described embodiments of the protection and treatment method according to the invention may further comprise the steps of: - a sacvitoli as defined herein for the manufacture of a medicament for use according to the invention use of a pharmaceutical composition comprising valsartan and valsartan in a molar ratio of 1:1; Sacubitril and valsartan as defined herein according to the invention in a molar ratio of 1: Use of a pharmaceutical composition comprising: - sacubitril and valsartan as defined herein for use according to the invention in a molar ratio of 1:1.
[0089] In particular, all of the above-described embodiments of the protection and treatment methods according to the present invention are A pharmaceutical composition for use in preventing or treating heart failure in a human pediatric patient according to the present invention. Use of the pharmaceutical composition for preventing or treating heart failure in a human pediatric patient according to the present invention and the manufacture of a medicament for the prevention or treatment of heart failure in a human pediatric patient according to the present invention. The present invention is equally applicable to the use of pharmaceutical compositions for
[0090] Some of these options are set out in the claims and form part of the disclosure. It shall be deemed that
[0091] Some of these aspects are further described in more detail below, but this description is not intended to be limiting. It should not be construed as limiting.
[0092] Compounds and compositions for use according to the invention In a preferred embodiment, the present invention provides a compound comprising [3-((1S,3R)-1-biphenyl-4 -ylmethyl-3-ethoxycarbonyl-1-butylcarbamoyl)propionic acid-(S )-3'-Methyl-2'-(pentanoyl{2''-(tetrazol-5-yl ate) Biphenyl-4'-ylmethyl}amino)butyric acid] trisodium hemipentahydrate (compound The present invention also includes pharmaceutical compositions for use containing a therapeutically effective amount of LCZ696. For the compounds and pharmaceutical compositions, see WO 2007 / 056546 and and WO 2009 / 061713, The preparation teachings are incorporated herein by reference.
[0093] In one embodiment of the present invention, for all of its uses, the pharmaceutical composition comprises an NEP inhibitor prodrug. The drug sacubitril, i.e., N-(3-carboxy-1-oxopropyl)-( 4S)-p-phenylphenylmethyl)-4-amino-(2R)-methylbutanoic acid ethyl ester Ester or NEP inhibitor N-(3-carboxy-1-oxopropyl)-(4S) -p-phenylphenylmethyl)-4-amino-(2R)-methylbutanoic acid, or pharmaceutical and the angiotensin receptor blocker valsartan or a pharmacologic acceptable salt thereof. Such combinations include those described, for example, in International Patent Application Publication No. 2003 / 013636 and their acceptable salts. No. 059345, incorporated herein by reference.
[0094] (i) Valsartan or (S)-N-valeryl-N-{[2'-(1H-tetrazolium acetate) phenyl-5-yl)-biphenyl-4-yl]-methyl}-valine) or a pharma- ceutically acceptable The salts can be purchased from commercial sources or are described in U.S. Pat. According to known methods, such as those described in US Pat. No. 5,578 and European Patent No. 0,443,983, It can be prepared accordingly, the teachings of which are incorporated herein by reference. Sartans may be used in certain embodiments of the present invention in their free acid form and any suitable salts. Optionally, esters or other derivatives of the carboxylic acid groups can be used. can be used, and salts and derivatives of the tetrazole group can be used.
[0095] (ii) Sacubitril, i.e., N-(3-carboxy-1-oxopropyl)-( 4S)-(p-Phenylphenylmethyl)-4-amino-2R-methylbutanoic acid ethyl ester ester or (2R,4S)-5-biphenyl-4-yl-4(3-carboxy-propyl (2-methyl-2-phenyl-1,3-diamino)-2-methylpentanoic acid is disclosed in U.S. Pat. They can be prepared by known methods, such as those described in US Pat. No. 5,217,996. can.
[0096] The pharmaceutical composition according to the present invention can be prepared by a method known per se, and can be administered to humans and other Suitable for oral or rectal, enteral, and parenteral administration to mammals (warm-blooded animals) and may be administered alone or in combination with one or more pharma- ceutically acceptable carriers, particularly enteral or parenteral. It contains a therapeutically effective amount of a pharmacologically active compound in combination with a carrier suitable for oral application.
[0097] The pharmaceutical preparations of the present invention may, for example, contain from about 0.1% to about 100%, for example 80%, of the active ingredient. or 90%, or from about 1% to about 60%, in each case as defined herein. The term "about" or "approximately" means within 10%, more preferably within 5%, of a given value or range. It shall have a meaning within %.
[0098] Pharmaceutical preparations according to the invention for enteral or parenteral administration are, for example, dragees, tablets, capsules. tablets, bars, sachets, granules, syrups, aqueous or oily suspensions or suppositories, These are in unit dose forms such as single tablets. It is prepared by conventional mixing, granulation, sugar-coating, dissolving or freeze-drying processes. Pharmaceutical preparations for oral use can be obtained by combining the active ingredient with a solid carrier. If desired, the resulting mixture may be granulated, the mixture or granules may be processed, and if desired, If necessary, tablets or dragee cores are obtained after the addition of suitable excipients.
[0099] Tablets are prepared by mixing the active compound and a filler, e.g. disintegrants, such as corn starch; lubricants, such as stearic acid; magnesium phosphate; binders such as microcrystalline cellulose or polyvinylpyrrolidone, and any other ingredients known to those skilled in the art. For example, hard or soft gelatin capsules containing the active compound with or without added excipients. The cell formulation can be prepared by known methods. The contents of the capsule are the active compound The pharmaceutical composition can be formulated using known methods to give a sustained release of the compound.
[0100] Other dosage forms for oral administration include, for example, sodium carboxymethylcellulose. Aqueous suspensions containing the active compound in an aqueous medium in the presence of a non-toxic suspending agent and a suitable Oil suspensions containing the active compound in a suitable vegetable oil, such as peanut oil.
[0101] The active compound may be formulated into granules with or without additional excipients. The agent may be ingested directly by the patient or may be added to a suitable liquid carrier (e.g., water) prior to ingestion. The granules may be supplemented with disintegrants, such as acids and carbon black, to facilitate dispersion in the liquid medium. The composition may contain an effervescent couple formed from a salt of an acid or a salt of a bicarbonate.
[0102] The dosage of the active ingredients of the composition will, of course, depend on the nature of the severity of the condition to be treated, the composition This will vary depending on the particular compound in the composition and its route of administration. It will also vary according to the age, weight and response of the patient.
[0103] The pharmaceutical composition for use in the context of the present invention may comprise [3-((1S,3R) -1-biphenyl-4-ylmethyl-3-ethoxycarbonyl-1-butylcarbamoyl ) Propionic acid -(S)-3'-methyl-2'-(pentanoyl {2''-(tetrazole (5-yl)biphenyl-4'-ylmethyl)amino)butyric acid] trisodium hemi In embodiments that include the pentahydrate (LCZ696), the therapeutic agents Sacubitril and Val The unit dose of sartan is 40 mg to 400 mg (e.g., 50 mg) per day. , 100mg, 200mg, 400mg) and so on, ranging from about 1 to about 1000mg. Alternatively, lower doses may be used, e.g., 0.5 to 100 mg / day; 0.5 to 50 mg / day or 0.5 to 20 mg can be given. Of note, the two drugs Sacubitri The unit dose of LCZ696 100 mg delivering 100 mg of valsartan and 100 mg of valsartan is 3-((1S,3R)-1-biphenyl-4-ylmethyl-3-ethoxycarbonyl-1 -butylcarbamoyl)propionic acid-(S)-3'-methyl-2'-(pentanoyl) 2''-(Tetrazol-5-yl)biphenyl-4'-ylmethyl}amino)butyrate equivalent to 113.1 mg of trisodium hemipentahydrate. 50mg is 56.6mg, 200mg is 226.2mg, and 400mg is 226.2mg. 00 mg contains 452.4 mg of [3-((1S,3R)-1-biphenyl-4-ylmethyl (S)-3'-(3-ethoxycarbonyl-1-butylcarbamoyl)propionic acid Methyl-2'-(pentanoyl{2''-(tetrazol-5-yl)ate)biphenyl Each requires trisodium (4'-ylmethyl)aminobutyrate hemipentahydrate. do.
[0104] The individual compounds Sacubitril and Valsartan or their combination in a pharmaceutical composition The total dosage for each salt ranges from about 1 to about 1000 mg, such as 40 mg to 400 mg. These include, but are not limited to, 5mg, 20mg, 25mg, 40mg, 50mg, 8mg, Includes 0mg, 100mg, 200mg, 400mg, 800mg and 1000mg Such dosages of the individual compounds Sacubitril and Valsartan are therapeutically effective. The ratio of the amounts of each compound in the pharmaceutical composition may be considered as efficacy or dosage strength. or about a 1:1 molar ratio. The amount of each compound in the pharmaceutical composition to achieve a therapeutic effect The ratio of is preferably about 1:1 molar ratio. In a preferred embodiment, the individual compounds Dosages of Sacubitril and Valsartan are available in doses of 50 mg, 100 mg, and 200 mg. or 400 mg of LCZ696. A 200 mg dose of CZ696 contains approximately 103 mg of valsartan and 97 mg of sacubitril. Equivalent to mg.
[0105] In one embodiment of the invention, the solid unit dosage form is in the form of a mini-tablet, said mini-tablet The formulation contains an effective amount of the active ingredient, between about 2 mg and about 5 mg per mini-tablet, particularly in the form of a mini-tablet. Approximately 2.5 mg to 4.0 mg per tablet, with a 1:1 molar ratio of valsartan (free The preferred amounts correspond to the combined amounts of sacubitril (free acid) and sacubitril (free acid). In an embodiment, each mini-tablet contains an effective amount of 3.125 mg per tablet as defined. Contains ingredients.
[0106] In one embodiment, the active ingredient is provided in the form of LCZ696. The effective amount is the weight of the two active ingredients, not including the weight of sodium and bound water contained in the complex. Based on the weight of Sacubitril and Valsartan; i.e. LCZ696 in mini tablets The effective amount of LCZ696 is between about 2 mg and about 5 mg per unit dosage form, particularly about 1 mg per unit dosage form. In one embodiment of the present invention, each small The tablet contains 3.125 mg of LCZ696 as defined. Taking into account the water of hydration and the amount of 3-((1S,3R)-1-biphenyl-4 -ylmethyl-3-ethoxycarbonyl-1-butylcarbamoyl)propionic acid-(S )-3'-Methyl-2'-(pentanoyl{2''-(tetrazol-5-yl ate) Biphenyl-4'-ylmethylamino)butyric acid trisodium hemipentahydrate per tablet The dosage form contains between about 3 mg and about 4 mg, preferably about 3.534 mg.
[0107] The pharmaceutical compositions used in the present invention may be administered in an immediate release or, less frequently, extended or sustained release form. As an emitter, any number of times per day, i.e., once a day (qd), twice a day (bi d.), three times, four times, etc. Preferably, the pharmaceutical composition is administered twice a day ( Corresponding doses can be taken, for example, in the morning, midday or evening. This can be done.
[0108] Embodiments of the present invention: Each of the following embodiments provides alternative claim language for countries where method of treatment claims are not available. The second medical use claim must be in the so-called Swiss format:
[0109] Embodiment 1: For use in preventing or treating heart failure in a human pediatric patient, a molar ratio Includes a therapeutically or prophylactically effective amount of a 1:1 combination of Sacubitril and Valsartan Pharmaceutical compositions.
[0110] Embodiment 2: A method according to embodiment 1, wherein the human pediatric patient is aged from 1 month to less than 18 years. Pharmaceutical compositions for use.
[0111] Embodiment 3: An embodiment in which the patient suffers from chronic heart failure due to left ventricular systolic dysfunction. 2. A pharmaceutical composition for use according to claim 1 or 2.
[0112] Embodiment 4: The patient is 6 to <18 years of age and is in NYHA class II, III or Patients with Ross HF classification II to IV or patients younger than 6 years of age 4. The pharmaceutical composition for use according to any one of embodiments 1 to 3, wherein the patient has heart failure.
[0113] Embodiment 5: The patient has a systemic left ventricular ejection fraction (LVEF) of ≦40%, preferably ≦35; or a shortening rate of ≦20% for use according to any one of embodiments 1 to 4. Pharmaceutical compositions.
[0114] Embodiment 6: The patient is a patient with a congenital heart defect with systemic ventricular systolic dysfunction; an idiopathic cardiomyopathy; a familial / Genetic and / or genetic cardiomyopathy; history of myocarditis; neuromuscular disorders; inborn errors of metabolism; Mitochondrial disorders; acquired (chemotherapy, iatrogenic, infectious, rheumatic, nutritional); ischemic have a heart failure etiology selected from the following: 6. A pharmaceutical composition for use according to any one of embodiments 1 to 5.
[0115] Embodiment 7: The patient is diagnosed with left ventricular systolic dysfunction due to NYHA class II, III or Patients suffering from chronic heart failure classified as IV, in which the patient has a reduced The use according to any one of embodiments 1 to 6, wherein the patient has a reduced left ventricular ejection fraction (LVEF). A pharmaceutical composition for use in treating
[0116] Embodiment 8: Administration reduces the risk of cardiovascular death and hospitalization due to heart failure in said patient. 8. The pharmaceutical composition for use according to any one of the preceding embodiments 1 to 7, which reduces
[0117] Embodiment 9: A combination of Sacubitril and Valsartan in a molar ratio of 1:1 is prepared by the compound [3 -((1S,3R)-1-biphenyl-4-ylmethyl-3-ethoxycarbonyl-1- (S)-3'-methyl-2'-(pentanoyl)propionate {2 ''-(Tetrazol-5-yl)biphenyl-4'-ylmethyl}amino)butyric acid ]A previous embodiment in which the compound is delivered in the form of trisodium hemipentahydrate (LCZ696). A pharmaceutical composition for use according to any one of aspects 1 to 8.
[0118] Embodiment 10: A therapeutically effective amount of a combination of Sacubitril and Valsartan in a 1:1 molar ratio. Or the prophylactically effective amount is about 10 mg to about 500 mg of sacubitril and Any of the preceding embodiments 1 to 9, comprising a total daily dose of a combination of valsartan and A pharmaceutical composition for use by
[0119] Embodiment 11: A therapeutically effective amount of a combination of Sacubitril and Valsartan in a 1:1 molar ratio Alternatively, the prophylactically effective amount is from about 2 mg / kg patient body weight to about 8 mg / kg body weight, preferably about 6 mg / kg body weight, especially 6.2 mg / kg body weight, sacubitril in a molar ratio of 1:1 and Any of the preceding embodiments 1 to 10, including a total daily dose of the combination of valsartan. A pharmaceutical composition for use by
[0120] Embodiment 12: A combination of Sacubitril and Valsartan in a 1:1 molar ratio is administered once daily. 12. Any of the preceding embodiments 1 to 11, wherein the compound is administered to the patient once or twice a day, preferably twice a day. A pharmaceutical composition for use by
[0121] Embodiment 13: A therapeutically effective amount of a combination of Sacubitril and Valsartan in a 1:1 molar ratio. Alternatively, a prophylactically effective amount is about 2 mg / kg to about 4 mg / kg of patient body weight administered twice daily. kg body weight, preferably approximately 3 mg / kg body weight, in particular 3.1 mg / kg body weight, in a molar ratio of 1 13. The method of any one of preceding embodiments 2 to 12, comprising administering to said patient a combination of sacubitril and valsartan of: A pharmaceutical composition for use according to any one of the preceding claims.
[0122] Embodiment 14: A combination of Sacubitril and Valsartan in a molar ratio of 1:1 per tablet Each tablet contains 3.125 mg of active ingredients (sacubitril and valsartan in a 1:1 molar ratio). In the form of one or more mini-tablets each containing 50 mg, 100 mg, or mg or 200 mg of the ingredients (sacubitril and valsartan in a 1:1 molar ratio) 14. Any one of the preceding embodiments 2 to 13, wherein the compound is administered to a patient in the form of a tablet containing A pharmaceutical composition for use by
[0123] Embodiment 15: a) A 50 mg dose of Sacubitril and Valsartan in a 1:1 molar ratio was Corresponding to 24mg and valsartan 26mg, b) A 100 mg dose of Sacubitril and Valsartan in a 1:1 molar ratio was 49 mg of valsartan and 51 mg of valsartan. c) A 1:1 molar ratio of Sacubitril and Valsartan at a dose of 200 mg was administered corresponding to 97 mg of valsartan and 103 mg of valsartan. A pharmaceutical composition for use according to embodiment 14.
[0124] Embodiment 16: Sacubitril and valsartan in a molar ratio of 1:1 are prepared by the compound, [3-( (1S,3R)-1-Biphenyl-4-ylmethyl-3-ethoxycarbonyl-1-butyric acid (S)-3'-methyl-2'-(pentanoyl{2'' -(Tetrazol-5-yl)biphenyl-4'-ylmethyl}amino)butyric acid]3 Delivered in the form of sodium hemipentahydrate (LCZ696) a) Sacubitril and valsartan 50 mg in a 1:1 molar ratio were administered at approximately Corresponding to 56.6mg, b) Sacubitril and valsartan 100 mg in a 1:1 molar ratio were administered in combination with LCZ696 and That corresponds to 113.1 mg. c) Sacubitril and valsartan 200 mg in a 1:1 molar ratio were administered in combination with LCZ696 and That corresponds to 226.2 mg. d) Sacubitril and valsartan 3.125 mg in a 1:1 molar ratio were administered in LCZ696 A pharmaceutical composition for use according to embodiment 15, corresponding to approximately 3.534 mg.
[0125] Embodiment 17: The method of any preceding embodiment, further comprising one or more pharma- ceutically acceptable carriers. A pharmaceutical composition for use according to any one of Forms 1 to 16.
[0126] Embodiment 18: Preventing or reducing the risk that the patient will experience a recurrent cardiovascular event. 18. The method of any one of the preceding embodiments 1 to 17, wherein the patient is concurrently receiving standard of care treatment to prevent or reduce the progression of the disease. or a pharmaceutical composition for use by one of the
[0127] Embodiment 19: The standard of care treatment comprises beta-blockers, aldosterone antagonists and / or or a pharmaceutical composition for use according to embodiment 18, comprising treatment with a stable dose of a diuretic. thing.
[0128] Embodiment 20: The standard of care treatment comprises beta-blockers and optionally aldosterone The pharmaceutical composition for use according to embodiment 18, comprising treatment with a stable dose of the antagonist.
[0129] Embodiment 21: Manufacture of a medicament for use in preventing or treating heart failure in a human pediatric patient. A therapeutically effective amount of a combination of Sacubitril and Valsartan in a molar ratio of 1:1 for Use of a pharmaceutical composition comprising a prophylactically effective amount.
[0130] Embodiment 22: The method of embodiment 21, wherein the human pediatric patient is aged from 1 month to less than 18 years. Use of the pharmaceutical composition according to claim 1.
[0131] Embodiment 23: The patient is suffering from chronic heart failure due to left ventricular systolic dysfunction. 23. Use of a pharmaceutical composition according to aspect 21 or 22.
[0132] Embodiment 24: The patient is 6 to under 18 years of age and has NYHA class II, III or had heart failure IV or the patient was younger than 6 years and had a Ross HF classification of II to I Use of a pharmaceutical composition according to any one of embodiments 21 to 23 in patients with heart failure of V.
[0133] Embodiment 25: The patient has a systemic left ventricular ejection fraction (LVEF) of ≦40%, preferably ≦35. or a shortening rate of ≦20%. Use of compositions.
[0134] Embodiment 26: The patient is a patient with a congenital heart defect with systemic ventricular systolic dysfunction; an idiopathic cardiomyopathy; a family member Gender / genetic and / or hereditary cardiomyopathy; history of myocarditis; neuromuscular disorders; inborn errors of metabolism mitochondrial disorders; acquired (chemotherapy, iatrogenic, infectious, rheumatic, nutritional); ischemia and left ventricular noncompaction; 26. Use of a pharmaceutical composition according to any one of embodiments 21 to 25.
[0135] Embodiment 27: The patient is suffering from NYHA class II, III or IV pulmonary hypertension due to left ventricular systolic dysfunction. The patient suffers from chronic heart failure classified as IV, and the patient has a ≤40%, preferably ≤35% 27. Any one of the preceding embodiments 21 to 26, having a reduced left ventricular ejection fraction (LVEF). Use of the pharmaceutical composition according to the present invention.
[0136] Embodiment 28: Administration reduces the risk of cardiovascular death and hospitalization due to heart failure in said patient. 28. Use of a pharmaceutical composition according to any one of the preceding embodiments 21 to 27 to reduce
[0137] Embodiment 29: A combination of Sacubitril and Valsartan in a molar ratio of 1:1 is 3-((1S,3R)-1-biphenyl-4-ylmethyl-3-ethoxycarbonyl-1 -butylcarbamoyl)propionic acid-(S)-3'-methyl-2'-(pentanoyl) 2''-(Tetrazol-5-yl)biphenyl-4'-ylmethyl}amino)butyrate The prior art drug is delivered in the form of trisodium hemipentahydrate (LCZ696). 29. Use of a pharmaceutical composition according to any one of forms 21 to 28.
[0138] Embodiment 30: A therapeutically effective amount of a combination of Sacubitril and Valsartan in a 1:1 molar ratio. Or the prophylactically effective amount is about 10 mg to about 500 mg of sacubitril and 30. Any of the preceding embodiments 21 to 29, comprising a total daily dose of a combination of valsartan and or use of a pharmaceutical composition according to any one of the preceding claims.
[0139] Embodiment 31: A therapeutically effective amount of a combination of Sacubitril and Valsartan in a 1:1 molar ratio Alternatively, the prophylactically effective amount is from about 2 mg / kg patient body weight to about 8 mg / kg body weight, preferably about 6 mg / kg body weight, especially 6.2 mg / kg body weight, sacubitril in a molar ratio of 1:1 and Any of the preceding embodiments 21 to 30, including a total daily dose of the combination of valsartan Use of the pharmaceutical composition according to claim 1.
[0140] Embodiment 32: A combination of Sacubitril and Valsartan in a 1:1 molar ratio is administered once daily. 32. Any of the preceding embodiments 22 to 31, wherein the compound is administered to the patient once or twice a day, preferably twice a day. Use of a pharmaceutical composition comprising either one of the following:
[0141] Embodiment 33: A therapeutically effective amount of a combination of Sacubitril and Valsartan in a 1:1 molar ratio. Alternatively, a prophylactically effective amount is about 2 mg / kg to about 4 mg / kg of patient body weight administered twice daily. kg body weight, preferably approximately 3 mg / kg body weight, in particular 3.1 mg / kg body weight, in a molar ratio of 1 The preceding embodiments 22 to 32, comprising a combination of sacubitril and valsartan of: Use of a pharmaceutical composition according to any one of the preceding claims.
[0142] Embodiment 34: A combination of Sacubitril and Valsartan in a molar ratio of 1:1 is administered per tablet. Each tablet contains 3.125 mg of active ingredients (sacubitril and valsartan in a 1:1 molar ratio). In the form of one or more mini-tablets each containing 50 mg, 100 mg, or mg or 200 mg of the ingredients (sacubitril and valsartan in a 1:1 molar ratio) Any of the preceding embodiments 22 to 33, wherein the compound is administered to a patient in the form of a tablet containing Use of the pharmaceutical composition according to one.
[0143] Embodiment 35: a) A 50 mg dose of Sacubitril and Valsartan in a 1:1 molar ratio was Corresponding to 24mg and valsartan 26mg, b) A 100 mg dose of Sacubitril and Valsartan in a 1:1 molar ratio was 49 mg of valsartan and 51 mg of valsartan. c) A 1:1 molar ratio of Sacubitril and Valsartan at a dose of 200 mg was administered corresponding to 97 mg of valsartan and 103 mg of valsartan. Use of a pharmaceutical composition according to embodiment 34.
[0144] Embodiment 36: Sacubitril and valsartan in a molar ratio of 1:1 are prepared by the compound, [3-( (1S,3R)-1-Biphenyl-4-ylmethyl-3-ethoxycarbonyl-1-butyric acid (S)-3'-methyl-2'-(pentanoyl{2'' -(Tetrazol-5-yl)biphenyl-4'-ylmethyl}amino)butyric acid]3 Delivered in the form of sodium hemipentahydrate (LCZ696) a) Sacubitril and valsartan 50 mg in a 1:1 molar ratio were administered at approximately Corresponding to 56.6mg, b) Sacubitril and valsartan 100 mg in a 1:1 molar ratio were administered in combination with LCZ696 and That corresponds to 113.1 mg. c) Sacubitril and valsartan 200 mg in a 1:1 molar ratio were administered in combination with LCZ696 and That corresponds to 226.2 mg. d) Sacubitril and valsartan 3.125 mg in a 1:1 molar ratio were administered in LCZ696 Use of the pharmaceutical composition according to embodiment 34 or 35, corresponding to approximately 3.534 mg.
[0145] Embodiment 37: The pharmaceutical composition further comprises one or more pharma- ceutically acceptable carriers. 37. The use of a pharmaceutical composition according to any one of the preceding embodiments 21 to 36.
[0146] Embodiment 38: Preventing or reducing the risk that the patient will experience a recurrent cardiovascular event. 38. The method of any of the preceding embodiments 21 to 37, wherein the patient is simultaneously receiving standard of care treatment to Use of a pharmaceutical composition comprising either one of the following:
[0147] Embodiment 39: The standard of care treatment comprises beta-blockers, aldosterone antagonists and / or Or the use of a pharmaceutical composition according to embodiment 38, comprising treatment with a stable dose of a diuretic.
[0148] Embodiment 40: The standard of care treatment comprises beta-blockers and optionally aldosterone The use of the pharmaceutical composition according to embodiment 38, comprising treatment with a stable dose of the antagonist.
[0149] The following examples are illustrative, but are not intended to limit the scope of the invention described herein. do not have. [Example 1]
[0150] To evaluate the safety, tolerability, and pharmacokinetics of LCZ696 in pediatric patients with heart failure A single-dose study to evaluate efficacy and safety of LCZ696 compared with enalapril, followed by a 52-week study of LCZ696 compared with enalapril ( ClinicalTrials.gov identifier: NCT02678312).
[0151] Investigational drug LCZ696: LCZ696 is a supramolecular complex [3-((1S,3R)-1-biphenyl-4-yl Methyl-3-ethoxycarbonyl-1-butylcarbamoyl)propionic acid-(S)-3 '-Methyl-2'-(pentanoyl{2''-(tetrazol-5-yl)ate)biphenyl This refers to trisodium (4'-ylmethyl)aminobutyrate hemipentahydrate. The compound and its pharmaceutical composition are described in WO 2007 / 056546. and WO 2009 / 061713. , the teachings of whose preparation are incorporated herein by reference.
[0152] LCZ696, as a single compound, inhibits the activity of NEP (neutral endopeptidase EC 3.4.24 .11) Inhibitor prodrug AHU377 (N-(3-carboxy-1-oxopropyl )-(4S)-p-phenylphenylmethyl)-4-amino-(2R)-methylbutanoic acid ethyl ester) and the angiotensin receptor blocker valsartan. It is a first-in-class angiotensin receptor neprilysin inhibitor. AHU377 is a potent inhibitor of neutral endopeptidase by enzymatic cleavage. LBQ657 (N-(3-carboxy-1-oxopropyl)-(4S)-p-phenyl (4-amino-(2R)-methylbutanoic acid), and the enzyme is the primary enzyme responsible for the degradation of atrial natriuretic peptide.
[0153] Overall study design: This is for pediatric patients aged 1 month to 18 years with heart failure due to systemic left ventricular systolic dysfunction. A multicenter, open-label study to evaluate the safety, tolerability, and pharmacokinetics of LCZ696 in , a single-dose study, followed by a comparison of the efficacy and safety of LCZ696 with enalapril This is a 52-week randomized, double-blind, parallel-group, active-controlled study to evaluate
[0154] This study consists of two parts (Part 1 and Part 2). The purpose of Part 1 is to determine how the body The objective of this study was to evaluate how the drug LCZ696 is absorbed, distributed, and eliminated from the body. This will help determine the appropriate dose of LCZ696 for the second part of the study. In particular, in Part 1, the open-label study was conducted in a sequential overlapping fashion and down the age group order. There were three age groups (group 1: 6 to <18 years old; group 2: 1 to <6 years old; group 3: 1 month to A single-dose study in 36 pediatric HF patients (aged 1 month to <18 years) stratified by age group (age <1 year). The PK / PD of LCZ696 will be determined. Approximately 5 in group 1 to ensure that the 0% of patients will be enrolled between the ages of 6 and 11 years.
[0155] Group 1 (6 to <18 years old): Patients were recruited and given a single dose of LCZ696 0.8 mg / kg. LCZ696 3.1 mg / kg single dose (N=6 observations) The PK and PD of the LCZ696 analyte will be evaluated after the observation. The dose [3.1 mg / kg] is approximately 20 times the dose of LCZ696 in an adult weighing 65 kg. 0 mg.)
[0156] Group 2 (1 to <6 years old): Patients were recruited and given a single dose of LCZ696 0.8 mg / kg. (N=6 observations) followed by a single dose of LCZ696 3.1 mg / kg (N=6 observations) ) will be followed by evaluation of the PK and PD of the LCZ696 analytes.
[0157] Group 3 (1 month to less than 1 year old): Patients were recruited and given a single dose of LCZ696 0.8 mg / kg. PK and PD of LCZ696 analytes will be evaluated after dose administration (N=6 observations) Physiologically based pharmacokinetic (PBPK) simulation studies have demonstrated higher exposure in this age group. The higher dose (3.1 mg / kg) in Group 3 was not evaluated because it predicted adverse reactions. It becomes.
[0158] The PK and PD of the sacubitril / valsartan analyte were evaluated in a 0.8 mg / kg (N=6) (n=6 observations), followed by a 3.1 mg / kg (n=6 observations) dose (Group 3, which received the lower dose) The efficacy and safety of sacubitril / bacillin will be evaluated in each age group after administration of a single dose of sacubitril / bacillin. Patients receiving a single dose of 0.8 mg / kg rusartan were then treated with sacubitril / valproate. Patients will also have the option to receive the 3.1 mg / kg dose of 0.8 mg / kg If a patient who received the 3.1 mg / kg dose does not qualify for or declines the 3.1 mg / kg dose, of patients will be recruited to receive the 3.1 mg / kg dose.
[0159] Doses for subsequent arms will be adjusted based on safety information from previous arms. become.
[0160] The objective of Part 2 was to evaluate the efficacy and safety of enalapril and LC over 52 weeks of treatment in pediatric patients with heart failure. The objective of the second part is to compare the efficacy and safety of Z696. This is a double-blind, parallel-group, active-controlled study. Annual growth and safety data will be available. Eligible patients (N=360), stratified by type, were randomly assigned to receive either LCZ696 or enalapril. (target dose: 0.2 mg / kg bid; maximum 10 mg bid) The lack of validated efficacy endpoints in these patients may be due to the lack of clinical events, such as death. and emergency cardiac transplantation list / mechanical life support; worsening HF; and functional evaluation. Patients were randomized based on the mean age (NYHA / Ross) and patient-reported QoL outcome measures ( A new global ranking is obtained by ranking the This guided the development of secondary endpoints.
[0161] the purpose: The purpose of this study was to evaluate pediatric heart failure (HF) patients (aged 1 month to <18 years) over a 52-week period. Greater clinical treatment benefit with LCZ696 compared with enalapril over treatment duration The objective of this study is to determine whether the results of the study will be useful in determining whether the effect of the Part 2 will determine the dose for Part 2. Part 2 will evaluate the efficacy of LCZ6 compared to enalapril. The efficacy and safety of 96 will be evaluated.
[0162] Primary purpose: (details below) Part 1: The primary objective is to evaluate the efficacy and safety of LCZ696 after a single ascending dose in pediatric patients with HF. The objective of this study was to determine the pharmacokinetics (PK) and pharmacodynamics (PD).
[0163] Part 2: The primary objective is to evaluate whether LCZ696 has a global ranking in pediatric HF patients. Superior to enalapril for the treatment of heart failure as assessed using endpoints The next step is to determine whether
[0164] Second Objective Part 2: LCZ696 reduces the incidence of category 1 and 2 events (e.g., death and worsening HF) Determine whether it is superior to enalapril in reducing the time to first appearance of the complex See Table 1.
[0165] [Table 1]
[0166] Part 2: LCZ696 is an effective treatment for improving NYHA / Ross functional class in patients with enalapril To determine whether IFN-γ is superior to IFN-γ, see Table 2.
[0167] [Table 2]
[0168] Part 2: LCZ696 improves Patient Global Impression of Severity (PGIS) scores To determine whether it is superior to enalapril in improving
[0169] Part 2: Characterizing the population PK of LCZ696 exposure in pediatric patients with HF
[0170] Part 2: Safety and efficacy of LCZ696 compared with enalapril in pediatric patients with HF Assess tolerability
[0171] research patients The study population consisted of pediatric patients with HF between 1 month and 18 years of age who had systemic left ventricular systolic dysfunction. Part 1 will consist of at least 18 and up to 36 patients. Part 2 will randomize 360 patients at sites worldwide. For the second part, patients will be divided into three groups based on age: Group 1:6 group 1: 1 to < 18 years old; group 2: 1 to < 6 years old; group 3: 1 month to < 1 year old.
[0172] Eligible ages for study: 1 month to 17 years Study eligible gender: Both Accepting healthy volunteers: No
[0173] Selection criteria: Patients with chronic heart failure due to left ventricular systolic dysfunction and receiving chronic HF treatment (newly diagnosed (If not possible) NYHA classification II-IV (older children: 6 to 18 years old) or Ross CHF classification II~IV (young children: under 6 years old) Systemic ventricular ejection fraction ≤ 40% or shortening fraction ≤ 20% For Part 1 of the study: Patients were to receive the equivalent of at least 0.2 mg / kg of enalapril Must be taken · Systemic left and biventricular physiology
[0174] Exclusion criteria: -Patients with single ventricle or systemic right ventricle Listed for heart transplantation (National Organ Allocation Network status 1A) and Patients who are hospitalized (on inotropic medication or with an artificial heart) awaiting transplantation person Persistent or symptomatic ventricular dysrhythmias uncontrolled by drug or device therapy - 3 months after corrective cardiovascular surgery or corrective percutaneous intervention for congenital heart / cardiovascular disease Patients within Unoperated obstructive or severe regurgitant valvular heart disease, or significant systemic ventricular outflow tract obstruction or Patients with aortic arch obstruction Patients with restrictive or hypertrophic cardiomyopathy Active myocarditis Renal vascular hypertension Moderate to severe obstructive pulmonary disease Serum potassium > 5.3mmol / L History of angioedema Allergy or hypersensitivity to ACEI / ARB
[0175] Research Procedure:
[0176] [Table 3]
[0177] detail: Part 1: Primary outcome measures: Pharmacokinetics of LCZ696 analytes (Sacubitril, LBQ657 and Valsartan): Maximum plasma drug concentration (Cmax) [Time frame: 0, 0.5, 1, 2, 4, 8, 1 0 and optionally 24 hours]. By using noncompartmental methods, Cmax was determined for the LCZ696 analytes (sacubitril, LBQ657 and valsartan). This will be determined. Time to maximum plasma concentration (Tmax) [time frame: 0, 0.5, 1, 2, 4, 8, 10 and optionally 24 hours]. By using noncompartmental methods, T max for LCZ696 analytes (sacubitril, LBQ657 and valsartan) The decision will be made based on the above. Area under the plasma concentration-time curve from time 0 to infinity (AUCinf) and time 0 Area under the plasma concentration-time curve (AUClast) from 0 to the end of , 0.5, 1, 2, 4, 8, 10 and optionally 24 hours]. By using this method, AUCinf and AUClast were The results of the study will be determined for each of the following: Vitril, LBQ657 and Valsartan. Clearance from plasma (CL / F) [Time frames: 0, 0.5, 1, 2, 4, 8 days after dosing] , 10 and optionally 24 hours]. By using noncompartmental methods, CL / F for LCZ696 analytes (sacubitril, LBQ657 and valsartan) The decision will be made based on the above. · Time required for drug concentration to fall by half (T 1 / 2) [Time frame: 0, 0. 5, 1, 2, 4, 8, 10 and optionally 24 hours]. Using noncompartmental methods This resulted in a T 1 / 2 increase in the LCZ696 analytes (sacubitril, LBQ657 and Valsartan) will be decided. Plasma N-terminal pro-brain natriuretic peptide (NTproBNP) [Time frame: post-dose 0, 4, 8, or optional 24 hours. 24 hours after dosing, optional with blood volume restriction. Plasma cyclic guanosine monophosphate (cGMP) [Time frames: 0, 4, 8, and optional 24 post-dose [time]. 24 hours after dosing, blood volume restriction is optional. Urinary cGMP [Time frame: between 4 and 8 hours after dosing]. Urine sample at 0 hours (before dosing) and another urine sample will be collected between 4 and 8 hours after dosing. Plasma B-type natriuretic peptide (BNP) [Time frame: 0 (pre-dose), 4 and 5 (post-dose) and 8 hours]
[0178] Part 2: Primary outcome measures: Percentage of patients falling into each category based on global ranking [time Time frame: up to 52 weeks The global rankings include clinical events such as deaths, emergency cardiac transplant listings, and study terminations. Mechanical life support requirements at time of discharge, worsening heart failure (HF), New York Heart Association (NYHA) / Ross, Patient Global Impression of Severity (PGIS), Pediatric Quality of Life Based on the Physical Functioning domain of the PedsQL. The primary endpoint was The results are based on five categories that are ranked according to best prognosis.
[0179] Secondary outcome measures: Time to first occurrence of Category 1 or Category 2 event [Timeframe: 52 weeks]: Category 1: Death; United Nations Organ Allocation Network (UN) for heart transplant or equivalent OS) Status 1A list; Ventricular assist device (VAD) for life support at the end of the study / Extracorporeal membrane oxygenation (ECMO) / mechanical ventilation requirement. Category 2: Worsening HF (WHF) defined by signs and symptoms of WHF requiring intensification of HF treatment
[0180] Change from baseline in NYHA / Ross functional class [Time frame: baseline NYHA / Ross functional classes were administered over a 52-week double-blind treatment period. Patient Global Impression of Severity (PGIS) scores will be compared. Change from baseline in kale [Time frame: baseline to 52 weeks]. PGI The S-scale was used to evaluate the efficacy and safety of LCZ696 and enalapril over 52 weeks of double-blind treatment. will be compared.
[0181] Population PK of LCZ696 analytes (sacubitril, LBQ657 and valsartan): Clearance from plasma at steady state (CL,ss) [time frames: 2, 12, 52 weeks] The steady state population PK parameter clearance will be estimated and used in the model.
[0182] Population PK of LCZ696 analytes (sacubitril, LBQ657 and valsartan): Volume of distribution at steady state [time frames: 2, 12, 52 weeks]. Steady-state population PK parameters of distribution Meter volumes will be estimated and used in the model.
[0183] Population PK of LCZ696 analytes (sacubitril, LBQ657 and valsartan): Absorption rate constant at steady state (Ka,ss) [Time frames: 2, 12, 52 weeks]. Steady state The population PK parameter Ka will be estimated and used in the model.
[0184] Population PK of LCZ696 analytes (sacubitril, LBQ657 and valsartan): Time required for the drug concentration to decrease by half at steady state (T 1 / 2, ss) [Time frame: 2 The steady-state population PK parameter T1 / 2 was estimated and used in the model. This will be the case.
[0185] Population PK of LCZ696 analytes (sacubitril, LBQ657 and valsartan): Maximum plasma drug concentration at steady state (Cmax, ss) [Time frames: 2, 12, 52 weeks] The steady state population PK parameter Cmax will be estimated and used in the model.
[0186] Population PK of LCZ696 analytes (sacubitril, LBQ657 and valsartan): The minimum plasma concentration observed during the dosing interval at steady state, (Cmin, ss) [time [Window: 2, 12, 52 weeks] The steady-state population PK parameter Cmin was estimated and used in the model. This will be done.
[0187] Population PK of LCZ696 analytes (sacubitril, LBQ657 and valsartan): Area under the plasma concentration-time curve (AUC) from time 0 to the end of the dosing interval tau at steady state tau,ss) [Time frames: 2, 12, 52 weeks] Estimate steady-state population PK parameter AUC and use it as a model.
Claims
1. Preventing or Treating Heart Failure in a Human Pediatric Patient in Need of Prevention or Treatment of Heart Failure The method comprises administering to the patient a combination of Sacubitril and Valsartan in a molar ratio of 1:
1. administering to said patient an effective or prophylactically effective amount.
2. 10. The method of claim 1, wherein the human pediatric patient is between 1 month and less than 18 years of age.
3. 2. The method according to claim 1, wherein the patient suffers from chronic heart failure caused by left ventricular systolic dysfunction. The method described above.
4. The patient is between 6 and 18 years of age and has a NYHA class II, III or IV cardiac or the patient is under 6 years of age and has a Ross HF classification of II to IV. The method according to any one of claims 1 to 3, wherein the patient has heart failure.
5. said patient having a systemic ventricular left ventricular ejection fraction (LVEF) of ≦40%, preferably ≦35, or 5. The method of claim 1, having a shortening fraction of 20%.
6. The patient is a patient with a congenital heart defect with systemic ventricular systolic dysfunction; an idiopathic cardiomyopathy; a familial / hereditary and / or genetic cardiomyopathy; history of myocarditis; neuromuscular disorders; inborn errors of metabolism; mitochondrial vascular disorders; acquired (chemotherapy, iatrogenic, infectious, rheumatic, nutritional); ischemic (e.g. and left ventricular non-compaction; 6. The method according to any one of 1 to 5.
7. The patient is classified as having a NYHA class II, III, or IV disorder due to left ventricular systolic dysfunction. and wherein the patient suffers from a chronic heart failure of the same type as the patient, and the patient has a reduction of ≦40%, preferably ≦35%.
7. The method of claim 1, wherein the patient has a left ventricular ejection fraction (LVEF).
8. said administration reduces the risk of cardiovascular death and hospitalization due to heart failure in said patient; The method according to any one of claims 1 to 7,
9. The combination of Sacubitril and Valsartan in a molar ratio of 1:1 is S,3R)-1-biphenyl-4-ylmethyl-3-ethoxycarbonyl-1-butyl rubamoyl)propionic acid-(S)-3'-methyl-2'-(pentanoyl {2''-( Tetrazol-5-yl ester)biphenyl-4'-ylmethyl}amino)butyric acid]3-nat 9. Any of claims 1 to 8, wherein the compound is delivered in the form of sodium hemipentahydrate (LCZ696).
3. The method according to claim 1 .
10. The therapeutically effective amount of a combination of Sacubitril and Valsartan in a molar ratio of 1:1 or A prophylactically effective amount is about 10 mg to about 500 mg of sacubitril and valproate in a 1:1 molar ratio. The method according to any one of claims 1 to 9, comprising a total daily dose of said combination of sartans. Law.
11. The therapeutically effective amount of a combination of Sacubitril and Valsartan in a molar ratio of 1:1 or A prophylactically effective amount is from about 2 mg / kg of patient body weight to about 8 mg / kg of body weight, preferably about 6 mg / kg. g / kg body weight, in particular 6.2 mg / kg body weight, of sacubitril and balsa in a molar ratio of 1:1 The method according to any one of claims 1 to 10, comprising administering to said patient a total daily dose of said combination of rutan. Law.
12. The combination of sacubitril and valsartan in a 1:1 molar ratio is administered once or twice daily. The method according to any one of claims 1 to 11, preferably administered to the patient twice daily. Law.
13. The therapeutically effective amount or prophylactic dose of a combination of Sacubitril and Valsartan in a molar ratio of 1:1 Effective amounts include about 2 mg / kg to about 4 mg / kg of patient body weight administered twice daily; Preferably, about 3 mg / kg body weight, especially 3.1 mg / kg body weight, in a molar ratio of 1:
1.
13. The method according to claim 1, comprising the combination of vitrill and valsartan. Method of posting.
14. The combination of Sacubitril and Valsartan in a 1:1 molar ratio was 3.12 mg / tablet. Each tablet contains 5 mg of active ingredients (sacubitril and valsartan in a molar ratio of 1:1). or in the form of one or more mini-tablets each containing 50 mg, 100 mg or Each contains 200 mg of the components (sacubitril and valsartan in a molar ratio of 1:1).
14. The method of claim 1, wherein the pharmaceutical composition is administered to the patient in the form of a tablet.
15. a) Sacubitril and Valsartan 50 mg in a 1:1 molar ratio are Sacubitril 24 mg g and valsartan 26 mg, b) Sacubitril and Valsartan 100 mg in a 1:1 molar ratio mg and valsartan 51 mg, c) Sacubitril and Valsartan 200 mg in a 1:1 molar ratio, Sacubitril 97 15. The method of claim 14, wherein the valsartan is 100 mg and the valsartan is 103 mg.
16. Sacubitril and valsartan in a molar ratio of 1:1 were synthesized in the compound, [3-((1S,3R) -1-biphenyl-4-ylmethyl-3-ethoxycarbonyl-1-butylcarbamoyl )propionic acid -(S)-3'-methyl-2'-(pentanoyl {2''-(tetrazo {5-yl-5-yl-4-methyl-4-amino)butyric acid} trisodium hemiphenyl It is delivered in the form of a pentahydrate (LCZ696), a) Sacubitril and Valsartan 50 mg in a 1:1 molar ratio were administered in a dose of approximately 1:
1. Corresponding to 56.6 mg, b) Sacubitril and Valsartan 100 mg in a 1:1 molar ratio were This corresponds to 113.1 mg. c) Sacubitril and Valsartan 200 mg in a 1:1 molar ratio were administered in combination with LCZ696 and This corresponds to 226.2 mg. d) 3.125 mg of Sacubitril and Valsartan in a 1:1 molar ratio was added to LCZ696 16. The method of claim 15, corresponding to approximately 3.534 mg.
17. The combination of Sacubitril and Valsartan in a 1:1 molar ratio is 17. The method of claim 1, further comprising delivering the compound of claim 1 in the form of a pharmaceutical composition further comprising a biologically acceptable carrier.
2. The method according to any one of claims 1 to 11.
18. The patient is administered a targeted 18. The method of any one of claims 1 to 17, wherein the patient is simultaneously receiving a complementary therapeutic treatment.
19. The standard of care treatment is beta-blockers, aldosterone antagonists and / or diuretics.
20. The method of claim 18, comprising treatment with a stable dose.
20. The standard of care treatment includes stable administration of beta-blockers and optionally aldosterone antagonists.
20. The method of claim 18, comprising treatment by dose.
